Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms
Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders
Objectives: To provide guidance for the management of mood disorders, based on scientific
evidence supplemented by expert clinical consensus and formulate recommendations to …
evidence supplemented by expert clinical consensus and formulate recommendations to …
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry
Therapeutic Drug Monitoring (TDM) is a valid tool to optimise pharmacotherapy. It enables
the clinician to adjust the dosage of drugs according to the characteristics of the individual …
the clinician to adjust the dosage of drugs according to the characteristics of the individual …
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute …
Objectives. This 2013 update of the practice guidelines for the biological treatment of
unipolar depressive disorders was developed by an international Task Force of the World …
unipolar depressive disorders was developed by an international Task Force of the World …
AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011
Therapeutic drug monitoring (TDM), ie, the quantification of serum or plasma concentrations
of medications for dose optimization, has proven a valuable tool for the patient-matched …
of medications for dose optimization, has proven a valuable tool for the patient-matched …
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report
Objective: This report describes the participants and compares the acute and longer-term
treatment outcomes associated with each of four successive steps in the Sequenced …
treatment outcomes associated with each of four successive steps in the Sequenced …
The GABAergic deficit hypothesis of major depressive disorder
B Luscher, Q Shen, N Sahir - Molecular psychiatry, 2011 - nature.com
Increasing evidence points to an association between major depressive disorders (MDDs)
and diverse types of GABAergic deficits. In this review, we summarize clinical and preclinical …
and diverse types of GABAergic deficits. In this review, we summarize clinical and preclinical …
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
Background Conventional meta-analyses have shown inconsistent results for efficacy of
second-generation antidepressants. We therefore did a multiple-treatments meta-analysis …
second-generation antidepressants. We therefore did a multiple-treatments meta-analysis …
Psychopharmaka
MJ Lohse, J Seifert, S Bleich - Arzneiverordnungs-Report 2021, 2021 - Springer
Zusammenfassung Auf einen Blick Zusammenfassung Mit weit über 2 Milliarden DDD
stellen die Psychopharmaka eine der größten Arzneimittelgruppen dar. Dabei sind die seit …
stellen die Psychopharmaka eine der größten Arzneimittelgruppen dar. Dabei sind die seit …
Report by the ACNP Task Force on response and remission in major depressive disorder
This report summarizes recommendations from the ACNP Task Force on the
conceptualization of remission and its implications for defining recovery, relapse …
conceptualization of remission and its implications for defining recovery, relapse …